Expression of epidermal growth factor receptor in canine osteosarcoma: Association with clinicopathological parameters and prognosis

Veterinary Journal

Volumn 193, Issue 2, 2012, Pages 412-419

  Selvarajah, Gayathri T ^a,b   Verheije, Monique H ^a   Kik, Marja ^a   Slob, Adri ^a   Rottier, Peter J M ^a   Mol, Jan A ^a   Kirpensteijn, Jolle ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Canine; Epidermal growth factor receptor; Osteosarcoma; Prognosis; Tissue microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOG; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GENE EXPRESSION REGULATION; LUNG METASTASIS; MALE; NONHUMAN; OSTEOSARCOMA; PREDICTION; PRIMARY TUMOR; PROTEIN EXPRESSION; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR GENE;

ANIMALS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL LINE, TUMOR; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; MALE; OSTEOSARCOMA; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TISSUE ARRAY ANALYSIS;

CANIS FAMILIARIS;

EID: 84865865529     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2012.02.009     Document Type: Article

References (39)

1. Bacon N.J., Ehrhart N.P., Dernell W.S., Lafferty M., Withrow S.J. Use of alternating administration of carboplatin and doxorubicin in dogs with microscopic metastases after amputation for appendicular osteosarcoma: 50 cases (1999-2006). Journal of the American Veterinary Medical Association 2008, 232:1504-1510.
2. Barroga E.F., Kadosawa T., Okumura M., Fujinaga T. Establishment and characterization of the growth and pulmonary metastasis of a highly lung metastasizing cell line from canine osteosarcoma in nude mice. Journal of Veterinary Medical Science 1999, 61:361-367.
3. Brinkhof B., Spee B., Rothuizen J., Penning L.C. Development and evaluation of canine reference genes for accurate quantification of gene expression. Analytical Biochemistry 2006, 356:36-43.
4. Chun R., Kurzman I.D., Couto C.G., Klausner J., Henry C., MacEwen E.G. Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: A pilot study. Journal of Veterinary Internal Medicine 2000, 14:495-498.
5. Do S.I., Jung W.W., Kim H.S., Park Y.K. The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma. International Journal of Oncology 2009, 34:797-803.
6. Duran I., Garcia-Velasco A., Ballestin C., Garcia E., Martinez-Tello F., Pond G.R., Garcia-Carbonero R., Cortes-Funes H., Paz-Ares L. Expression of EGFR, HER-2/neu and KIT in germ cell tumours. Clinical and Translational Oncology 2010, 12:443-449.
7. Freeman B.B., Daw N.C., Geyer J.R., Furman W.L., Stewart C.F. Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Investigation 2006, 24:310-317.
8. Freeman S.S., Allen S.W., Ganti R., Wu J., Ma J., Su X., Neale G., Dome J.S., Daw N.C., Khoury J.D. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer 2008, 113:1453-1461.
9. Hong S.-H., Osborne T., Ren L., Briggs J., Mazcko C., Burkett S.S., Khanna C. Protein kinase C regulates ezrin-radixin-moesin phosphorylation in canine osteosarcoma cells. Veterinary and Comparative Oncology 2011, 9:207-218.
10. Gaafar R., Bahnassy A., Abdelsalam I., Kamel M.M., Helal A., Abdel-Hamid A., Eldin N.A., Mokhtar N. Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung Cancer 2010, 70:43-50.
11. Gama A., Gartner F., Alves A., Schmitt F. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in canine mammary tissues. Research in Veterinary Science 2009, 87:432-437.
12. Gorlick R., Huvos A.G., Heller G., Aledo A., Beardsley G.P., Healey J.H., Meyers P.A. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. Journal of Clinical Oncology 1999, 17:2781-2788.
13. Hadzisejdic I., Mustac E., Jonjic N., Petkovic M., Grahovac B. Nuclear EGFR in ductal invasive breast cancer: Correlation with cyclin-D1 and prognosis. Modern Pathology 2010, 23:392-403.
14. Higgins R.J., Dickinson P.J., LeCouteur R.A., Bollen A.W., Wang H., Wang H., Corely L.J., Moore L.M., Zang W., Fuller G.N. Spontaneous canine gliomas: Overexpression of EGFR, PDGFRα and IGFBP2 demonstrated by tissue microarray immunophenotyping. Journal of Neuro-Oncology 2010, 98:49-55.
15. Hughes D.P., Thomas D.G., Giordano T.J., Baker L.H., McDonagh K.T. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Research 2004, 64:2047-2053.
16. Hughes D.P., Thomas D.G., Giordano T.J., McDonagh K.T., Baker L.H. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatric Blood and Cancer 2006, 46:614-623.
17. Kersting C., Agelopoulos K., Schmidt H., Korsching E., August C., Gosheger G., Dirksen U., Juergens H., Winkelmann W., Brandt B., Bielack S., Buerger H., Gebert C. Biological importance of a polymorphic CA sequence within intron 1 of the epidermal growth factor receptor gene (EGFR) in high grade central osteosarcomas. Genes, Chromosomes and Cancer 2008, 47:657-664.
18. Kersting C., Gebert C., Agelopoulos K., Schmidt H., van Diest P.J., Juergens H., Winkelmann W., Kevric M., Gosheger G., Brandt B., Bielack S., Buerger H. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome. Clinical Cancer Research 2007, 13:2998-3005.
19. Kirpensteijn J., Kik M., Rutteman G.R., Teske E. Prognostic significance of a new histologic grading system for canine osteosarcoma. Veterinary Pathology 2002, 39:240-246.
20. McKillop D., Hutchison M., Partridge E.A., Bushby N., Cooper C.M., Clarkson-Jones J.A., Herron W., Swaisland H.C. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica 2004, 34:917-934.
21. McKillop D., Partridge E.A., Hutchison M., Rhead S.A., Parry A.C., Bardsley J., Woodman H.M., Swaisland H.C. Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. Xenobiotica 2004, 34:901-915.
22. Morris C.D., Gorlick R., Huvos G., Heller G., Meyers P.A., Healey J.H. Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clinical Orthopaedics and Related Research 2001, 382:59-65.
23. Oda Y., Wehrmann B., Radig K., Walter H., Rose I., Neumann W., Roessner A. Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: Its correlation with proliferating activities and p53 expression. General and Diagnostic Pathology 1995, 141:97-103.
24. Ozaki T., Schaefer K.L., Wai D., Buerger H., Flege S., Lindner N., Kevric M., Diallo R., Bankfalvi A., Brinkschmidt C., Juergens H., Winkelmann W., Dockhorn-Dworniczak B., Bielack S.S., Poremba C. Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas. International Journal of Cancer 2002, 102:355-365.
25. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research 2001, 29:e45.
26. Pinter F., Papay J., Almasi A., Sapi Z., Szabo E., Kanya M., Tamasi A., Jori B., Varkondi E., Moldvay J., Szondy K., Keri G., Dominici M., Conte P., Eckhardt S., Kopper L., Schwab R., Petak I. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. Journal of Molecular Diagnostics 2008, 10:160-168.
27. Rego R.L., Foster N.R., Smyrk T.C., Le M., O'Connell M.J., Sargent D.J., Windschitl H., Sinicrope F.A. Prognostic effect of activated EGFR expression in human colon carcinomas: Comparison with EGFR status. British Journal of Cancer 2010, 102:165-172.
28. Rimawi M.F., Shetty P.B., Weiss H.L., Schiff R., Osborne C.K., Chamness G.C., Elledge R.M. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 2010, 116:1234-1242.
29. Sabattini S., Marconato L., Zoff A., Morini M., Scarpa F., Capitani O., Bettini G. Epidermal growth factor receptor expression is predictive of poor prognosis in feline cutaneous squamous cell carcinoma. Journal of Feline Medicine and Surgery 2010, 12:760-768.
30. Selvarajah G.T., Kirpensteijn J., van Wolferen M.E., Rao N.A., Fieten H., Mol J.A. Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times. Molecular Cancer 2009, 8:72.
31. Shiomitsu K., Johnson C.L., Malarkey D.E., Pruitt A.F., Thrall D.E. Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumours. Veterinary and Comparative Oncology 2009, 7:106-114.
32. Shoieb A.M., Hahn K.A., Barnhill M.A. An in vivo/in vitro experimental model system for the study of human osteosarcoma: Canine osteosarcoma cells (COS31) which retain osteoblastic and metastatic properties in nude mice. In Vivo 1998, 12:463-472.
33. Shupnik M.A., Tashjian A.H. Functional receptors for epidermal growth factor on human osteosarcoma cells. Journal of Cellular Physiology 1981, 109:403-410.
34. Spee B., Penning L.C., van den Ingh T.S.G.A.M., Arends B., Ijzer J., van Sluijs F.J., Rothuizen J. Regenerative and fibrotic pathways in canine hepatic portosystemic shunt and portal vein hypoplasia, new models for clinical hepatocyte growth factor treatment. Comparative Hepatology 2005, 4:7.
35. Valabrega G., Fagioli F., Corso S., Madon E., Brach del Prever A., Biasin E., Linari A., Aglietta M., Giordano S. ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. British Journal of Cancer 2003, 88:396-400.
36. Wen Y.H., Koeppen H., Garcia R., Chiriboga L., Tarlow B.D., Peters B.A., Eigenbrot C., Yee H., Steiner G., Greco M.A. Epidermal growth factor receptor in osteosarcoma: Expression and mutational analysis. Human Pathology 2007, 38:1184-1191.
37. Witlox M.A., Van Beusechem V.W., Grill J., Haisma H.J., Schaap G., Bras J., Van Diest P., De Gast A., Curiel D.T., Pinedo H.M., Gerritsen W.R., Wuisman P.I. Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. Journal of Gene Medicine 2002, 4:510-516.
38. Wu H., Muscato N.E., Gonzalez A., Shyr Y. An EGFR and AKT signaling pathway was identified with mediation model in osteosarcomas clinical study. Biomarker Insights 2007, 2:469-476.
39. Yalcin B., Gedikoglu G., Kutluk T., Varan A., Akyuz C., Buyukpamukcu M. C-erbB-2 expression and prognostic significance in osteosarcoma. Pediatric Blood and Cancer 2008, 51:222-227.